Colgate-Palmolive: Improving Execution And A Valuation Discount Make It A Buy
CL Q3 deep dive: global demand and premium innovation support steady growth amid cost pressures
Morgan Stanley Maintains Overweight on Colgate-Palmolive, Raises Price Target to $111
BNP Paribas Reiterates Outperform on Colgate-Palmolive, Raises Price Target to $108
JP Morgan Maintains Overweight on Colgate-Palmolive, Lowers Price Target to $102
Loading...